According to the report “Global Respiratory Syncytial Virus Market” – Industry Dynamics, Market Size, and Opportunity Forecast to 2027” published by Astute Analytica, Respiratory Syncytial market has been estimated to have a CAGR of 14.9% during the forecast period, globally.
According to the report “Global Respiratory Syncytial Virus Market” – Industry Dynamics, Market Size, and Opportunity Forecast to 2027” published by Astute Analytica, Respiratory Syncytial market has been estimated to have a CAGR of 14.9% during the forecast period, globally.
Request Brochure of Report - https://www.astuteanalytica.com/request-sample/respiratory-syncytial-virus-market
RSV has few medications available, and few have been approved by the FDA for respiratory syncytial virus (RSV). Aerosolized ribavirin for treatment and palivizumab (Synagis) for prophylaxis are the main RSV antiviral medicines approved by the FDA for the treatment or prevention of significant respiratory tract infections caused by RSV. Palivizumab binds to the protein molecule existing in virus, forming a defense. Consequently, they do not infect human cells. While ribavirin is an antiviral agent that prevents the multiplication of the virus. However, ribavirin holds only 10% of the market share in RSV market because it has non-specific anti-RSV activity, relatively high cost and risks for potential toxicity.
In recent years, in addition to the FDA-approved RSV antivirals, new recombinant antibodies, nanobodies, and small compounds such as fusion inhibitors, nucleoprotein inhibitors, nucleoside analogues, and non-nucleoside inhibitors have been developed as additional therapies against RSV. For instance, MEDI8897 is a recombinant human IgG1 monoclonal antibody (mAb) with an altered Fc region for a prolonged serum half-life, and it was developed to prevent RSV-related lower respiratory tract disease (LRTI). The antibody binds to the RSV F protein's prefusion conformation. Similarly, a novel compound AK-0529 has been developed to inhibit RSV replication by blocking viral entry into the target cells.
The influence of key market drivers, such as the high prevalence of RSV and other related respiratory tract diseases around the world and the emergence of targeted therapy is analyzed in the report. According to the National Institute of Allergy and Infectious Disease (NIAID), RSV infects all children in the United States by the age of two with 75,000 to 125,000 children hospitalized each year. RSV affects an estimated sixty-four million people worldwide and causes deaths of 160,000 people each year. According to a report, the global RSV burden was 33.1 million in 2015, resulting in 3.2 million hospitalizations and 59,600 deaths among children. In the last ten years, the RSV season has usually preceded the influenza season, with the average commencement near the end of February. However, an RSV season has not been noticed in 2020, which was due to COVID-19 control measures that lowered RSV circulation. In 2020, the maximum number of positive RSV detections in a week was twenty-five, compared to up to sixty-five positive RSV detections per week in previous years. However, since late March, the National Respiratory and Enteric Virus Surveillance System (NREVSS), a statewide passive, laboratory-based surveillance network, has shown an upsurge in RSV detections. The CDC reported an increase in laboratory detections and positive detection percentages for both antigen and PCR tests around the world. According to research, repeated therapy with mAb, one injection per month over the first five winter months of an infant's life, reduces hospitalization cases by more than half.
RSV treatment is gaining more government support, and proactive government programs are providing lucrative opportunities.
The government has stated that it wants to work with the industry to create a beneficial climate. The federal government of the United States has played a vital role in the early development of sectors, not only through research and development, but also through financial support for start-up businesses and government procurement. In 2019, about eighty new research projects were financed, a 44 percent increase over the previous year's number of funded infectious applications. Reliable compensation outside of standard health insurance will be required for equitable access to novel therapies. For example, the CDC Vaccines for Children (VFC) program will certainly be necessary for children from low-income or uninsured families. Prior to regulatory approvals for new interventions, policymakers and public health professionals will need to create new channels to promote access.
The World Health Organization has launched the BRaVe (Battle Against Respiratory Viruses) campaign, which aims to reduce the public health (severe disease) and economic impact of viral respiratory infections by filling knowledge gaps, developing innovative therapeutic and preventive interventions, and proposing comprehensive strategies that include viral etiologies. Along with pharmaceutical corporations, government agencies are included in the list of preclinical vaccine developers. As a result of government investment and backing, the market is predicted to grow at a profitable rate.
North America region is dominating the Respiratory Syncytial (RSV) Market Globally
Among all the regions in the global market including Europe, Asia Pacific, North America, Middle East, and Africa (MEA) and South America, it is expected that North America have the largest hold in the global RSV market in 2021 because of an increased rate of infection in the area. A survey of RSV hospitalizations coded as ICD-9 in the United States estimated an RSV hospitalization rate of 3,860/100,000 among children under the age of six months and 80/100,000 in children aged two to four years.
In countries like Japan and Australia, there is a higher prevalence of respiratory syncytial virus medications in established healthcare institutions, which has helped the RSV market in APAC grow at the fastest CAGR of 17 percent throughout the projection period. Countries with strong healthcare infrastructure, such as Japan and Australia, have a higher penetration of respiratory syncytial virus treatments in the region. Furthermore, the market expansion is since the prevalence of RSV differs by ethnicity and environment in different countries around the area.
Competitive Landscape
Major players covered in this report are AstraZeneca, AbbVie, Inc., Bausch Health Companies, Inc., Pfizer, Inc., SOBI, GlaxoSmithKline, and others. To stay competitive in the market, these companies are conducting clinical studies on RSV candidate vaccines and treatments, and they have drugs in their pipeline. GlaxoSmithKline has started a Phase III clinical trial in 2021 to investigate the immunogenicity, safety, and persistence of its Respiratory Syncytial Virus (RSV) candidate vaccine for older adults (GSK3844766A). GSK's proprietary AS01 adjuvant, which is also used in GSK's shingles vaccine, is paired with a recombinant subunit pre-fusion RSV antigen (RSVPreF3) in the RSV candidate vaccine for older adults. Pfizer, on the other hand, acquired ReViral and its Respiratory Syncytial Virus Therapeutic Candidates in April 2022. The proposed acquisition will boost Pfizer's expertise in infectious disease research and development, as well as a complementary strategy to help improve patient outcomes by treating respiratory syncytial virus infections and preventing sickness through vaccination. Pfizer's anti-infective portfolio is being expanded, and the company's R&D, manufacturing, and commercialization expertise are being put to work to fulfil an enormous unmet demand for RSV medications.
Segment Summary
Market size analysis based on revenue distribution of different segments include drug type, dosage form, treatment type, distribution channel and region. For instance, the oral route is dominating the dosage form segment in the market because it is the simplest, most convenient, and safest means of drug administration. Oral route administration is convenient for repeated and prolonged use.
Similarly, immune prophylaxis dominated the market with a 65% share in 2021, while antiviral drugs segment is expected to rise at a CAGR of 15.9% during the projection period.
The report provides thorough analysis of Respiratory Syncytial Virus (RSV) Market – Industry Dynamics, Market Size and Opportunity Forecast to 2027, based on the following:
- By Drug Type
- Synagis
- Virazole
- Palivizumab
- Riba Tab
- Others
- By Dosage Form
- Oral
- Injectable
- Inhaler
- Others
- By Treatment Type
- Immune Prophylaxis
- Supportive Care
- Antiviral Medications
- By Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Clinics
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- The UK
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Argentina
- Brazil
- Rest of South America
- North America
Read More – https://www.astuteanalytica.com/industry-report/respiratory-syncytial-virus-market
For Additional Information OR Media Enquiry, Please Mail Us At: sales@astuteanalytica.com
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact us:
Aamir Beg BSI Business Park, H-15,Sector-63, Noida- 201301- India
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
Email: sales@astuteanalytica.com
Website: www.astuteanalytica.com
Follow US: LinkedIn | Twitter